Exploration on the mechanism of Guben Qingyuan Prescription in delaying Enzalutamide resistance in prostate cancer by targeting the Wnt/β-catenin and SDF-1/CXCR4 dual pathway of cancer stem cells regulated by cancer-associated fibroblasts in the tumor microenvironment